search
Back to results

Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation (REX)

Primary Purpose

Cough, Hypertension

Status
Completed
Phase
Phase 4
Locations
Colombia
Study Type
Interventional
Intervention
Remifentanil
Sponsored by
Fundacion Clinica Valle del Lili
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cough focused on measuring Cough, Hypertension, Remifentanil, Sevoflurane, Desflurane

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Study Population:

Patients undergoing planned surgery who want to avoid coughing during emergence and extubation (Head and Neck Surgery, abdominal, neurosurgery and intraocular)

Inclusion Criteria:

  • American Society of Anesthesia status I and II
  • Age between 18 to 60 years.
  • Elective surgery.

Exclusion Criteria:

  • Uncontrolled hypertension. (SBP> 180 mmHg) at pre anesthesia area.
  • Active or uncontrolled pulmonary disease.
  • Signs or history of difficult airway.
  • Recent respiratory infection.
  • Train-of-four (TOF) index <90% at the end of surgery.
  • Patients who have received some form of pre oral medication.
  • Body mass Index above 30 kg/m2.
  • Concomitant use of epidural catheter.
  • Urgent surgery.

Sites / Locations

  • Fundacion Valle del Lili

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Sevo-2.0

Sevo-2.5

Des-2.0

Des-2.5

Sevo-Control

Des-Control

Arm Description

This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.

This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.

This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.

This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.

This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.

This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.

Outcomes

Primary Outcome Measures

Cough during emergency from anesthesia
Assess the presence and intensity of cough : 0) No cough, 1) A single episode of cough, 2) More than one episode of nonsustained cough, 3) sustained and repetitive cough with head elevation.

Secondary Outcome Measures

Cardiac response during emergence from anesthesia
Assessment of heart rate (bpm) during awakening and tracheal extubation: Measurements of systolic blood pressure will be obtained at the time of suspending of the halogenated (Basal 2) , eye opening, tracheal extubation and 2.5 minutes after extubation
Pressor response during emergence from anesthesia
Assessment of systolic blog pressure (mmHg) during awakening and tracheal extubation: Measurements of systolic blood pressure will be obtained at the time of suspending of the halogenated (Basal 2) , eye opening, tracheal extubation and 2.5 minutes after extubation
Time to eye opening
Time in seconds from inhaled anesthetic discontinuation to eye opening response to call by name and touch stimuli.
Time to tracheal extubation
Time in seconds from inhaled anesthetic discontinuation to safety conditions for tracheal extubation (patients must respond positively to three different commands: "open your eyes " , "breath deep " and "open your mouth ")
Halogenated end tidal concentration at tracheal extubation
Inhaled gas concentration measured in vol % by the gas analyzer at tracheal extubation
Respiratory rate during post-extubation
Number of breaths per minute during spontaneous ventilation.
Post-extubation hypoxemia
Continuous non-invasive measurement of the percentage of hemoglobin that is attached to oxygen through a pulse oximeter . Episodes of arterial oxygen saturation less than 92% , which is present in the next 10 minutes to extubation were recorded and encourage the patient to breathe through call and tactile stimulation as necessary during this time. If you arrived 10 minutes after extubation the patient continues to present desaturation because bradypnea / intermittent apnea the same process will continue until the patient has spontaneous ventilation ( breathing without any verbal or tactile stimulation ) .
Rescue analgesia requirement in the immediate postoperative time
Amount of opioid requirements for rescue analgesia during first postoperative hour (other opioids dose will be converted to equipotent milligrams of morphine.
Postoperative nausea and vomiting
Rated on a scale of 0-3, representing presence and intensity of nausea and / or vomiting within the first postoperative hour 0 = no nausea = mild nausea without vomiting episodes = nausea and a single episode of vomiting = more than one episode of vomiting during the first hour

Full Information

First Posted
April 25, 2014
Last Updated
April 28, 2017
Sponsor
Fundacion Clinica Valle del Lili
search

1. Study Identification

Unique Protocol Identification Number
NCT03132519
Brief Title
Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation
Acronym
REX
Official Title
Optimal Remifentanil Site-effect Concentration for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation After Sevoflurane vs. Desflurane. A Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
October 2013 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fundacion Clinica Valle del Lili

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Pain, cough, hypertension and tachycardia are frequent events during extubation due to a secondary stimulation of mechanoreceptors located in the airway. The mechanical effect of the endotracheal tube activates autonomic reflexes, a situation that could potentially impair the clinical condition of patients. Previous studies have used remifentanil during emergence and extubation showing good results to control this reflex response. However, it is unknown so far, the optimal effect site concentration (Ce) of remifentanil to allow a better control of these events with a low incidence of adverse effects after have received inhaled anesthesia plus remifentanil for anesthetic maintenance. This study will determine the Ce of remifentanil associated with a lower proportion of cough and hyperdynamic circulatory response during extubation for emergency after exposure to sevoflurane or desflurane.
Detailed Description
Single-center, randomized, double-blind protocol. The investigators aim to include 368 patients under balanced anesthesia with sevoflurane or desflurane to be randomly allocated into 6 different remifentanil Ce groups [77 individuals in each of interventional groups (2.0 vs. 2.5 ng/ml) and 30 in each of the control groups (1.0 ng/ml) administrated by a target-controlled infusion (TCI) system during emergence and tracheal extubation . Once informed consent is obtained and inclusion/exclusion criteria are met, subjects will be randomized before starting of the surgical procedure. This information will remain blinded to the attendant anesthesiologist and the independent evaluator during the process of extubation, except for type of inhaled anesthetic for maintenance . The intervention will start when the anesthesiologist decide to suspend the sevorane or desflurane dial. At this moment, the fresh flow gas of the anesthesia machine will be adjusted to 7-8 liters per minute and the infusion of remifentanil will be set up to establish a Ce of 2.0 ng/ml or 2.5 ng/ml. All patients will be extubated only when all of these three parameters exist: response to name by eyes opening, response to orders of breathing and mouth opening. The evaluation and outcomes measurement will include: Presence and intensity of cough and changes in heart rate and blood pressure during eyes opening in response to calling by name, tracheal extubation and 2.5 min after, time to get to be extubated after inhaled anesthetic discontinuation, episodes of hypoxemia and sedation state during the first 25 minutes after extubation, requirements of rescue analgesia and postoperative nausea and vomit during this period. Close monitoring of patients will take place and data will be collected during the preoperative, intraoperative and postoperative stages until discharge from the post anesthesia care unit. Lost to follow and adverse events will be assessed. An interim committee will evaluate partial results of the study when it reaches 25 and 50% of recruitment, so the investigators can continue building thereof according to analysis obtained. Statistical analysis will be performed by a independent statistician based on "intention to treat" principle. In addition, excluded data and its reasons for exclusion will be evaluated. For the descriptive exploratory analysis, continuous variables will be presented as means (standard deviation) or medians (interquartile ranges). The degree of dispersion, shape and position as the fulfillment of normality will be analyzed using the t of Student or Mann-Whitney tests as appropriate. Categorical variables will be presented as proportions and compared using the chi-square or Fisher 's exact tests as appropriate. Time-varying measures analysis of variance for repeated measures will be used to make comparisons between groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cough, Hypertension
Keywords
Cough, Hypertension, Remifentanil, Sevoflurane, Desflurane

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
364 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sevo-2.0
Arm Type
Experimental
Arm Description
This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.
Arm Title
Sevo-2.5
Arm Type
Experimental
Arm Description
This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
Arm Title
Des-2.0
Arm Type
Experimental
Arm Description
This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
Arm Title
Des-2.5
Arm Type
Experimental
Arm Description
This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
Arm Title
Sevo-Control
Arm Type
Active Comparator
Arm Description
This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
Arm Title
Des-Control
Arm Type
Active Comparator
Arm Description
This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
Intervention Type
Drug
Intervention Name(s)
Remifentanil
Other Intervention Name(s)
Ultiva
Intervention Description
To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
Primary Outcome Measure Information:
Title
Cough during emergency from anesthesia
Description
Assess the presence and intensity of cough : 0) No cough, 1) A single episode of cough, 2) More than one episode of nonsustained cough, 3) sustained and repetitive cough with head elevation.
Time Frame
From eye opening up to 2.5 minutes after tracheal extubation
Secondary Outcome Measure Information:
Title
Cardiac response during emergence from anesthesia
Description
Assessment of heart rate (bpm) during awakening and tracheal extubation: Measurements of systolic blood pressure will be obtained at the time of suspending of the halogenated (Basal 2) , eye opening, tracheal extubation and 2.5 minutes after extubation
Time Frame
From discontinuation of inhalational anesthetics up to 2.5 minutes after tracheal extubation
Title
Pressor response during emergence from anesthesia
Description
Assessment of systolic blog pressure (mmHg) during awakening and tracheal extubation: Measurements of systolic blood pressure will be obtained at the time of suspending of the halogenated (Basal 2) , eye opening, tracheal extubation and 2.5 minutes after extubation
Time Frame
From discontinuation of inhalational anesthetics up to 2.5 minutes post-extubation
Title
Time to eye opening
Description
Time in seconds from inhaled anesthetic discontinuation to eye opening response to call by name and touch stimuli.
Time Frame
From inhaled anesthetic discontinuation until the moment of eye opening response to verbal command (calling by name), assessed up to 20 minutes.
Title
Time to tracheal extubation
Description
Time in seconds from inhaled anesthetic discontinuation to safety conditions for tracheal extubation (patients must respond positively to three different commands: "open your eyes " , "breath deep " and "open your mouth ")
Time Frame
From inhaled anesthetic discontinuation until the event of tracheal extubation, assessed up to 20 minutes.
Title
Halogenated end tidal concentration at tracheal extubation
Description
Inhaled gas concentration measured in vol % by the gas analyzer at tracheal extubation
Time Frame
From eyes opening until the event of tracheal extubation, assessed up to 20 minutes.
Title
Respiratory rate during post-extubation
Description
Number of breaths per minute during spontaneous ventilation.
Time Frame
From tracheal extubation to 25 minutes later
Title
Post-extubation hypoxemia
Description
Continuous non-invasive measurement of the percentage of hemoglobin that is attached to oxygen through a pulse oximeter . Episodes of arterial oxygen saturation less than 92% , which is present in the next 10 minutes to extubation were recorded and encourage the patient to breathe through call and tactile stimulation as necessary during this time. If you arrived 10 minutes after extubation the patient continues to present desaturation because bradypnea / intermittent apnea the same process will continue until the patient has spontaneous ventilation ( breathing without any verbal or tactile stimulation ) .
Time Frame
From tracheal extubation to 25 minutes
Title
Rescue analgesia requirement in the immediate postoperative time
Description
Amount of opioid requirements for rescue analgesia during first postoperative hour (other opioids dose will be converted to equipotent milligrams of morphine.
Time Frame
From tracheal extubation up to first postoperative hour
Title
Postoperative nausea and vomiting
Description
Rated on a scale of 0-3, representing presence and intensity of nausea and / or vomiting within the first postoperative hour 0 = no nausea = mild nausea without vomiting episodes = nausea and a single episode of vomiting = more than one episode of vomiting during the first hour
Time Frame
From tracheal extubation to first postoperative hour

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Study Population: Patients undergoing planned surgery who want to avoid coughing during emergence and extubation (Head and Neck Surgery, abdominal, neurosurgery and intraocular) Inclusion Criteria: American Society of Anesthesia status I and II Age between 18 to 60 years. Elective surgery. Exclusion Criteria: Uncontrolled hypertension. (SBP> 180 mmHg) at pre anesthesia area. Active or uncontrolled pulmonary disease. Signs or history of difficult airway. Recent respiratory infection. Train-of-four (TOF) index <90% at the end of surgery. Patients who have received some form of pre oral medication. Body mass Index above 30 kg/m2. Concomitant use of epidural catheter. Urgent surgery.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fredy G Ariza, MD., MSc.
Organizational Affiliation
Fundacion Clinica Valle del Lili
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ivan F Quintero, MD
Organizational Affiliation
Fundacion Clinica Valle del Lili
Official's Role
Study Chair
Facility Information:
Facility Name
Fundacion Valle del Lili
City
Cali
State/Province
Valle
ZIP/Postal Code
76001000
Country
Colombia

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data available for future validations at institutional database system from Clinical Research Center, Fundación Valle del Lili of

Learn more about this trial

Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation

We'll reach out to this number within 24 hrs